Início › Câncer de Pulmão de Não Pequenas Células › New Hampshire
Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em New Hampshire
17 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em New Hampshire.
Cidades em New Hampshire
Texto oficial do estudo (Inglês)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT07155187Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT04267848Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Dartmouth-Hitchcock Medical Center, Lebanon
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Dartmouth Hitchcock Medical Center, Lebanon
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667076Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Lebanon
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06767514A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Dartmouth Hitchcock Medical Center, Lebanon
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT04302025A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Dartmouth Hitchcock Medical, Lebanon
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06253871A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04165798KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04165070Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de jun. de 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecrutandoFase 2
18 Minutes · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06031688A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Dartmouth Hitchcock, Lebanon
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de abr. de 2026 · NCT06362369A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- Dartmouth Hitchcock Medical Center, Lebanon
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de mar. de 2026 · NCT05948865Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.